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Abstract 
Chromatin undergoes structural changes in response to extracellular and environmental signals. We 
observed changes in nuclear morphology in cancer tissue biopsied after chemotherapy and 
hypothesised that these DNA damage-induced changes are mediated by histone deacetylases 
(HDACs). Nuclear morphological changes in cell lines (PE01 and PE04 models) and a xenograft model 
(OV1002) were measured in response to platinum chemotherapy by image analysis of nuclear 
texture. HDAC2 expression increased in PEO1 cells treated with cisplatin at 24h, which was 
accompanied by increased expression of heterochromatin protein 1 (HP1). HDAC2 and HP1 
expression were also increased after carboplatin treatment in the OV1002 carboplatin-sensitive 
xenograft model but not in the insensitive HOX424 model. Expression of DNA damage response 
pathways (pBRCA1, γH2AX, pATM, pATR) showed time-dependent changes after cisplatin treatment. 
HDAC2 knockdown by siRNA reduced HP1 expression, induced DNA double strand breaks (DSB) 
measured by γH2AX, and interfered with the activation of DNA damage response induced by 
cisplatin. Furthermore, HDAC2 depletion affected γH2AX foci formation, cell cycle distribution, and 
apoptosis triggered by cisplatin, and was additive to the inhibitory effect of cisplatin in cell lines. By 
inhibiting expression of HDAC2, reversible alterations in chromatin patterns during cisplatin 
treatment were observed. These results demonstrate quantifiable alterations in nuclear morphology 
after chemotherapy, and implicate HDAC2 in higher order chromatin changes and cellular DNA 
damage responses in ovarian cancer cells in vitro and in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Chromatin structure is dynamic, and changes occur in response to extracellular and 
environmental signals [1]. Histone tail acetylation is an important chromatin modification that alters 
DNA accessibility to regulating enzymes by transforming chromatin from a compact to relaxed 
structure that is permissive of gene expression [2, 3]. The balance between histone acetyltransferase 
(HAT) and histone deacetylase (HDAC) activities ultimately determines acetylation status [4]. Histone 
acetylation is involved with cellular differentiation, mitosis and meiosis, DNA transcriptional 
regulation, DNA damage, DNA replication, and circadian rhythms [5, 6, 7, 8]. 
Mammalian HDACs are grouped into four classes based on structural homology, enzymatic 
activity, and cellular localisation [9, 10, 11, 12]. Class I HDACs (HDAC 1, 2, 3, and 8) are mainly 
nuclear, and they interact with histones and other proteins [13, 14], while class II HDACs (HDAC 4, 5, 
6, 7, 9, and 10) are tissue-specific and can be both nuclear and cytoplasmic [13]; the majority of 
HDAC inhibitors inhibit both class I and class II enzymes [15, 13]. Class III HDACs, namely sirtuins 
(SIRTs1 – 7; silent information regulators), are unresponsive to most HDAC inhibitors but require the 
cofactor NAD+. Finally, the class IV HDAC, HDAC11, is expressed in the nucleus and shares homology 
with class I and class II HDACs [15, 16].  
HAT and HDAC activity can be altered by mutation, overexpression, or translocation, 
disrupting the acetylation-deacetylation balance and consequently contributing to cancer hallmarks; 
these epigenetic changes have been observed in leukaemia and prostate, breast, colorectal, and 
ovarian cancers [17, 13]. Acetylation changes are thought to participate in carcinogenesis by 
silencing tumor suppressor gene promoters, such as p21, [18, 19], activation of repressed genes, or 
abnormal recruitment of HATs or HDACs [13]. 
The heterochromatin protein 1 (HP1) protein family plays various roles in establishing and 
maintaining heterochromatin (tightly-packed DNA) structure, thereby repressing transcription [20]. 
HP1 overexpression can cause global gene repression and chromatin condensation [21, 22]. The 
three human HP1 isoforms, HP1α, HP1β, and HP1γ, share functions and localise to chromatin with 
incomplete overlap [23], differentially localising to centric heterochromatin, telomeres, and specific 
euchromatic sites [24]. Alterations in HP protein expression have been identified in some cancers 
including ovarian [25], breast [26], and colorectal cancer [27].  
We have observed changes in nuclear structure in clinical samples of cancer tissue after 
treatment with chemotherapy and radiotherapy. Since structure dictates gene expression and, 
therefore, function, we sought to investigate this phenomenon to better understand therapeutic 
responses. We hypothesised that nuclear morphological changes in cancer in response to DNA 
damage are mediated by HDACs and are associated with changes in HP1 protein expression and/or 
nuclear distribution. Initial studies indicated changes in expression of HDAC2, therefore, we explored 
whether HDAC2 mediated response to injury and might act as a resistance factor to DNA-damaging 
therapy. 
 
Results 
Nuclear structure changes after chemotherapy or radiotherapy in ovarian cancer cells 
Preliminary observations by light microscopy suggested that nuclear morphology was 
different in clinical tumors after treatment with chemotherapy and radiotherapy (Figure 1). To 
explore this phenomenon further, chromatin patterns were quantified by nuclear texture image 
analysis in an ovarian cancer cell line model. Texture features were regarded as positively or 
negatively associated with chromatin patterns (homogeneity, heterogeneity, and contrast) as 
previously described [28, 29]. Five parameters associated with texture were obtained: angular 
second moment (ASM), correlation, entropy, inverse different moment (IDM) and contrast. ASM is a 
strong measure of uniformity or smoothness associated with overall homogeneity of chromatin 
patterns. Correlation calculates the grey-level linear dependency of the image and correlates 
negatively with the heterogeneity of chromatin patterns. Entropy measures pattern disorder and is 
negatively correlated with homogeneity. Inverse different moment (IDM) measures the local 
variability and intensity of a region of interest (ROI) and is affected by image homogeneity, with non-
homogeneous areas normally resulting in low IDM values; thus, it is described as the ‘contrast’ of 
chromatin patterns.  
PE01 ovarian cancer cells [30] grown on coverslips were treated with cisplatin or ionising 
radiation and incubated for 0h, 6h, 12h and 24h. After 24 h treatment with 6 μM cisplatin or 6 Gy 
radiation, all five image texture parameters measured changed compared to untreated controls; 
observations were similar for both cisplatin and radiation. ASM, correlation, and IDM decreased 
after cisplatin/radiation treatment by 20%/23%, 25%/49%, and 15%/11%, respectively, while 
entropy and contrast increased by 6%/8% and 40%/120%. The heterogeneity and contrast of 
chromatin increased and the homogeneity decreased in cell nuclei after DNA damage-inducing 
treatment with cisplatin and radiation, consistent with the observations made by light microscopy. 
 
Measurement of nuclear texture changes in response to carboplatin in vivo 
We next sought to establish whether similar nuclear changes occur in vivo using a platinum-
sensitive OV1002 patient-derived ovarian cancer xenograft model [31]. Carboplatin, a cisplatin 
analogue, was used as this drug is commonly used clinically. After a single treatment with 
carboplatin, ovarian cancer xenografts were collected on days 0, 1, 2, 4, 7, and 14. Haematoxylin and 
eosin (H&E) staining and light microscopy indicated similar morphological changes to those seen in 
vitro (Figure 1). Untreated tumors tended to have strongly stained and homogeneous nuclei, while 
nuclei after carboplatin treatment had more lightly stained nuclei and greater heterogeneity (Figure 
2B). When nuclear texture was analysed by image analysis, texture parameters were different in 
samples after carboplatin treatment compared to controls, with the most significant effects of 
single-dose carboplatin typically seen two days after treatment (entropy and IDM p=0.034 and 
0.008, respectively; Figure 2C), indicating that chromatin pattern changes occur after platinum 
treatment in vivo and in vitro (Figure 2D). 
HDACs are differentially expressed in platinum-resistant cell lines 
It has previously been shown that HDAC1, HDAC3, and HDAC4 might be associated with 
resistance to chemotherapy and poor prognosis in cancer patients [32 - 34]. To investigate whether 
HDACs are involved in DNA damage-based treatment, we measured protein expression of HDAC 
class I (HDAC1, 2, 3, and 8) and IIA (HDAC4) members in PEO1 and PEO4 cells 24h after cisplatin 
treatment. The PE04 cell line was derived from the same patient as the PE01 cell line but after 
resistance had developed [30]. Since changes in nuclear texture after cisplatin treatment were most 
pronounced at 24 h, we speculated that HDACs would similarly show maximal changes at this time 
point. HDAC2 expression was increased approximately 1.5 fold in cisplatin-treated PEO1 cells, but 
not in PE04 cells, compared to controls at 24 h. Expression of HDACs 1, 3, 4 and 8 were unchanged in 
both cell lines after 24h (data not shown). This suggests that HDAC2 might be a cisplatin response 
biomarker in vitro, at least in sensitive cells. HP1 heterochromatin isoforms were also measured 
after cisplatin treatment (Figure 3A). Two HP1 isoforms (HP1α and HP1β) increased by about 30% 
and 70%, respectively, but only in PEO1 cells after 24 h cisplatin treatment, while HP1γ protein 
remained static. 
To visualise and confirm these observations, immunofluorescence (IF) was performed on 
PEO1 and PEO4 cells with or without cisplatin treatment using antibodies targeting HDAC2, HP1α, 
HP1β, and HP1γ (Figure 3B). As expected, expression of HDAC2 increased 24 h after cisplatin 
treatment, and HP1 proteins gradually increased over 24 h of cisplatin treatment in PEO1 cells 
(Figure 3B). Again no changes were observed in PEO4 cells (data not shown). The IF images 
confirmed nuclear localisation of these targets.  
Since HDAC2 and HP1 protein expression changed after cisplatin treatment in PEO1 cells, we 
next measured mRNA expression. Transcription of HDAC2, HP1α, HP1β, and HP1γ were all 
significantly elevated by cisplatin treatment (p<0.05) after 24 h in PEO1 cells (Figure 3C), mirroring 
the protein expression changes; however, mRNA levels remained unchanged in PEO4 cells (data not 
shown). The changes in HP1 expression suggest that the amount of heterochromatin increases after 
DNA-damaging treatment. 
 
Profiling expression of HDAC and HP1 proteins in ovarian cancer xenograft models 
We then examined HDAC and HP1 expression in the platinum-sensitive OV1002 and 
platinum-resistant HOX424 xenograft models [31]. HDAC2 and all three HP1 proteins were 
significantly increased in the sensitive model (OV1002) after carboplatin treatment, with the most 
significant changes (p<0.05) observed on day 7 (Figure 4). In the HOX424 model, expression of these 
proteins was similar between control and treated groups. 
 
Time-dependent cellular DNA damage response induced by cisplatin in ovarian cancer cells 
We next investigated several DNA damage response (DDR) pathway members (γH2AX, 
pBRCA1, ATM, pATM, ATR, and pATR) by western blotting (Figure 5). As expected, the DNA damage 
response proteins pBRCA1, γH2AX, pATM, and pATR participated in the response to cisplatin and 
were upregulated after treatment. pBRCA1 expression increased after 24 h of cisplatin treatment in 
PEO1 cells, which persisted to 96 h, while γH2AX, pATM, and pATR increases occurred slightly later 
from 48 h. ATM and ATR protein expression remained stable except for ATM reductions at 96 h. 
 
Expression profiling of other HDAC family members, heterochromatin proteins, and DNA damage 
response proteins under HDAC2 suppression 
Given that HDAC2 expression showed the most pronounced changes in response to cisplatin, 
we examined the effect of HDAC2 knockdown by siRNA (Figure 6A). HDAC2 knockdown was efficient 
(Supplementary Figure 1). Expression of HDAC3, HDAC4, and HDAC8 were not significantly affected 
by HDAC2 knockdown. Interestingly, HDAC1 expression was mildly upregulated after HDAC2 
knockdown, indicating a possible compensatory effect as previously reported [35 - 37]. Since HDAC2 
was implicated in heterochromatin formation, we further assessed HP isoform expression after 
HDAC2 knockdown (Figure 6A). There were minor changes in HP1 protein expression, with mild 
downregulation (20%) of HP1α on HDAC2 knockdown. With respect to DNA damage response 
protein expression, HDAC2 knockdown resulted in marked upregulation of γH2AX and 
downregulation of pBRCA1 (Figure 6A). In contrast, other DDR proteins (pATM, ATM, pATR, ATR, and 
Rad51; Figure 6A) were not obviously affected. This suggests that double-strand breaks accumulate 
and DNA repair might be suppressed on HDAC2 knockdown, although the upregulation of γH2AX 
might also indicate that the cells are undergoing apoptosis [38]. 
  
Characterisation of cellular responses to cisplatin treatment in ovarian cancer cells when HDAC2 is 
suppressed 
We next investigated the potential role of HDAC2 in cisplatin response. PE01 cells were 
treated with cisplatin after HDAC2 knockdown (Figure 6B). HDAC2 was consistently upregulated at 
24 h and downregulated at later time points in response to cisplatin without HDAC2 knockdown. 
Unsurprisingly, the induction of double-strand breaks (DSBs) indicated by γH2AX expression 
occurred as early as 6 h, while γH2AX expression increased after 24 h of cisplatin treatment in cells 
depleted of HDAC2 compared to cisplatin-treated or HDAC2 knockdown groups. This accumulation 
diminished over 72 h. As expected, pBRCA1, pATM, pATR, and Rad51 participated in the DNA 
damage response triggered by cisplatin at certain time points (6h, 24h, 48h, and 24h) and were 
upregulated. In contrast, cisplatin reduced expression of these proteins in cells with HDAC2 
knockdown from 24h to 72h (Figure 6B). 
The cisplatin-resistant PEO4 cell line was next studied to further clarify the involvement of 
HDAC2 during cisplatin-induced DNA damage responses (Supplementary Figure 2). There was little 
change in HDAC2 expression in PEO4 cells during cisplatin treatment, except for decreased 
expression at 72 h. In contrast to PEO1 cells, the cumulative effect of HDAC2 depletion and cisplatin 
treatment on γH2AX was not observed in PEO4 cells, although induction of DSBs was noted from 24 
h in response to cisplatin alone. Additionally, pBRCA1, pATM, and RAD51 were upregulated by 
cisplatin treatment alone. Expression of these proteins was suppressed by HDAC2 depletion, 
although the pattern of expression over time was different to PEO1 cells. 
 
 
Role of HDAC2 in γH2AX foci formation during cisplatin treatment 
γH2AX foci at DNA damaged domains are indicative of inter-strand crosslinking by cisplatin [39]. The 
detection of ser139-phosphorylated γH2AX foci has been widely used to evaluate double-strand 
breaks (DSBs) [40]. Therefore, γH2AX foci were targeted and visualised using immunofluorescence 
microscopy (Figure 7). γH2AX foci were formed in PEO1 (Figure 7) and PE04 cells in response to 
cisplatin (Supplementary Figure 3). Similarly, HDAC2 knockdown resulted in γH2AX foci in both cell 
lines (Figure 7 and Supplementary Figure 3). There was a marked increase (number and intensity) in 
γH2AX foci in PEO1 cells treated with cisplatin after HDAC2 knockdown, which was less pronounced 
in PEO4 cells, similar to cisplatin alone (Supplementary Figure 3). Using a cut-point of five foci per 
cell as negative background, the number of foci-positive PEO1 cells significantly increased after 
cisplatin treatment, HDAC2 knockdown, and cisplatin treatment in HDAC2-depleted cells (p<0.05 
and 0.01 compared to cisplatin-treated and siRNA-transfected groups, respectively; Figure 7). In 
PE04 cells, cisplatin induced foci (p<0.001), while HDAC2 knockdown did not.  
Cell fate determination by HDAC2 knockdown during cisplatin treatment 
We assessed the effect of HDAC2 knockdown on cell fate with and without cisplatin 
treatment. Growth inhibition by cisplatin was concentration dependent manner in both control 
HDAC2 knockdown groups in PEO1 cells (Figure 8A). Cisplatin treatment alone induced significant S-
phase arrest in PEO1 cells (+160%, p<0.001) and decreased the number of G1-phase cells (-30%; 
p<0.05) (Figure 8B). HDAC2 knockdown alone increased the S phase population (+120%, p<0.05). As 
expected, cisplatin treatment in HDAC2-depleted cells altered the cell cycle distribution in PEO1 
cells, but in a different way: HDAC2 knockdown caused further S-phase arrest induced by cisplatin in 
PEO1 cell (+120%, p<0.05) and an additional reduction in G1 phase cells (-20%, p<0.001). In contrast, 
HDAC2 depletion seemed to reduce S-phase accumulation (-20%, p<0.001) and increase the G1-
phase population (+140%, p<0.05) based on measurements of cisplatin treated cells without 
transfection. 
We next analysed the effect of cisplatin and HDAC2 knockdown on apoptosis (Figure 8C). 
Cisplatin induced early apoptosis (annexin V positive only) (p<0.001). HDAC2 knockdown caused 
both early and late apoptosis (p<0.001). Furthermore, HDAC2 depletion induced significant 
(especially early) apoptosis after cisplatin treatment (p<0.001). 
Reversibility of HDAC inhibition on nuclear morphological changes during cisplatin treatment 
To test if the nuclear structural changes were mediated by HDACs, then specifically HDAC2, 
we investigated whether the nuclear changes were reversible by applying either the broad-spectrum 
HDAC inhibitor trichostatin A (TSA) or HDAC2 siRNA in PEO1 cells. When PEO1 cells were treated 
with TSA, all five texture parameters were altered: angular second moment, correlation, and inverse 
difference moment increased, while entropy and contrast decreased (Figure 9A). Decreased 
chromatin heterogeneity and contrast and increased homogeneity are consistent with HDAC 
inhibition relaxing the chromatin structure. With HDAC2 siRNA (Figure 9B), comparable changes to 
TSA were observed. 
 
Discussion 
Within this study, we show that comparable nuclear morphological changes occur in several 
ovarian tumor models (cell lines and xenografts) after treatment-induced cellular damage. Image 
analysis of nuclear texture has previously been used to differentiate between benign and malignant 
cancers [28], examine apoptotic cells [41], and study the condensation and distribution of chromatin 
in the nucleus in drug-sensitive and resistant cells [42]. In the present study, increased nuclear 
heterogeneity was assumed to indicate a transition from euchromatin to heterochromatin. 
Consistent with this, HP1 isoform expression increased after cisplatin treatment in vitro, which was 
accompanied by enhanced expression of HDAC2 at both the mRNA and protein levels. Studies in vivo 
using a patient-derived ovarian cancer xenograft model also showed elevated HDAC2 and HP1 
isoform expression after chemotherapy.  
As an essential component of heterochromatin, HP1 accumulates in response to UV or 
ionising radiation consistent with chromatin reorganisation [43]. We obtained a similar result, with 
enhanced heterochromatin formation following chemotherapy both in vivo and in vitro. HDAC2 was 
upregulated after 24h of cisplatin treatment in vitro, with similar results seen in vivo in ovarian 
cancer xenografts. In line with its function as a regulator of condensed chromatin formation, HDAC2 
expression changed consistent with the observed changes in nuclear texture and was a possible 
mediator of the DNA damage response. This alteration in chromatin pattern might also indicate that 
chemotherapy induces transcriptional silencing, perhaps as a form of cellular self-protection upon 
injury. There is evidence that HDAC-containing complexes including Mi-2/NuRD and/or Sin3/HDAC 
chromatin-modifying complex (containing HDAC1 and HDAC2) participate in nuclear reorganisation 
and gene repression during development [44]. Mi-2/NuRD and mSin3/HDAC co-repressor complexes 
are also necessary for pericentric heterochromatin assembly and chromosome segregation [45, 46].  
There were time-dependent changes in the expression of DNA damage response proteins 
including pBRCA1, γH2AX, pATM, and pATR after cisplatin treatment in PEO1 cells. As a marker of 
double strand breaks, elevated γH2AX expression indicated activation of DSB repair pathways in 
response to cisplatin treatment in PEO1 cells; there is evidence to show that the tumor suppressor 
function of BRCA1 occurs via heterochromatin silencing, with increased levels of both 
heterochromatin and BRCA1 observed after DNA damage [47]. Our results are consistent with these 
findings, and suggest that chromatin remodelling by HDACs is involved in the cellular response to 
DNA damage therapy such as double strand break and DNA repair.  
HDACs are associated with malignancy and poor clinical outcomes in multiple cancer types [13, 17]. 
Roles for HDAC2 have been identified in a variety of malignancies. In colon cancer cells, HDAC2 
expression has been associated with chemoresistance to genotoxic stress [48]. In neuroblastoma, 
HDAC2 has been show to act with N-MYC to reduce TP53INP1 expression which influences p53 
phosphorylation at serine 46, with subsequent effects on cell proliferation and survival [49]. In 
leukemia, HDAC2 silencing induces modulation of gene expression leading to strong transcriptional 
activation [50] while in lung cancer, HDAC2 has been proposed to exert an effect on survival by 
sustaining Mdm2-survivin levels [51]. A number of studies have demonstrated efficacy of combined 
HDAC inhibitor and cytotoxic chemotherapy. The HDAC inhibitor romidepsin (FK228), approved for 
phase I and II trials, enhances the cytotoxic effects of cisplatin by reducing cell growth and inducing 
more DNA damage-induced cell death in vitro and in vivo [52]. Since HDAC2 in particular was 
associated with early responses to cisplatin in our cell culture studies, cell growth was evaluated in 
response to HDAC2 knockdown. HDAC2 depletion reduced the IC50 of cisplatin in PEO1 cells, 
suggesting that HDAC2 loss enhances the effect of cisplatin treatment. Repression of cell growth in 
chemo-sensitive PEO1 cells by cisplatin after HDAC2 silencing appeared to be due to accumulated S-
phase arrest and apoptosis.  
Cell cycle progression blockade has been reported to occur as a result of checkpoint 
activation during DNA damage-based therapy, and at least one checkpoint protein, Chk1, is 
upregulated during intra-S-phase accumulation by affecting chromatin formation and interfering 
with the initiation and elongation of DNA replication [53]. It is feasible that HDAC2 interacts with 
checkpoint proteins to prevent DNA replication by condensing the chromatin in self-protection, and 
triggers apoptosis via distinct pathways in platinum sensitive and resistant cells. Several mechanisms 
have been suggested to explain HDAC inhibitor-induced apoptosis, such as altered transcription and 
DDR and DNA damage repair [54-56]. The early upregulation (after 24 h) of HDAC2 in sensitive cells 
may suggest that HDAC2 is acting as a sensor of DNA damage and a trigger of downstream DDR 
events (such as activation of ATM, ATR, and BRCA1) and chromatin remodelling, followed by histone 
hyperacetylation to relax the chromatin structure and facilitate recruitment of more DDR mediators 
to the damaged site.  
DSBs (measured by γH2AX) accumulated after 24 h of cisplatin treatment in HDAC2-depleted 
PEO1 cells, but not PEO4 cells. High γH2AX expression has previously been associated with cell 
viability and apoptosis in ovarian cancer [57], which was attributed to the cell type tested and time 
after damage. H2AX activation has also been noted a number of days after treatment with an HDAC 
inhibitor, suggesting that increased γH2AX expression precedes cancer cell death [58]. Suppression 
of DDR activation (as evidenced by pATM, pATR, pBRCA1, and RAD51 expression) after HDAC2 
knockdown strongly suggests that HDAC2 is involved in responses to DNA damage-based treatment. 
The differences between PEO1 and PEO4 cells in DSB accumulation and time of pathway activation 
or suppression is consistent with the observed differences in cell cycle progression, and also might 
be due their differences in cisplatin sensitivity. The two major pathways of DSB repair, non-
homologous end joining (NHEJ) and homologous recombination (HR), appear to compensate for 
each other [59], and their balance might be disrupted by the known BRCA2 deficiency in PEO1 and 
secondary mutation to restore BRCA2 in PE04 [60]. This might influence the dominant mechanism of 
repair in the two cell lines and cause differences in the observed functional activity of the measured 
DNA damage response proteins after cisplatin treatment. 
Together, these results suggest that chromatin remodelling caused by increased HDAC2 
expression might be an early cellular event (within 24 h) in response to DNA damage. We postulate 
that, in sensitive tumors, early alterations in chromatin induced by chemotherapy and mediated by 
histone deacetylation are a form of cellular self-defence to injury by repressing transcription, 
initiating chemotherapy-triggered DDR, and promoting survival. This is followed by a change to a 
relaxed chromatin conformation by histone hyperacetylation, such as via H3k56Ac and H4k16Ac, to 
provide accessibility of DNA to downstream proteins at damaged sites [61 - 63]. However, resistant 
tumors behave differently in terms of their response to DNA damage to chemotherapy; this might be 
due to their initial chromatin environment or due to other changes in the components of the DDR 
response pathways in which HDACs participate. In one study, HDAC1/2-associated immediate 
histone hypoacetylation occurred after laser microirradiation of a human osteosarcoma cell line to 
promote NHEJ, which was followed by hypoacetylation to enhance HR and guard genome integrity 
[64], supporting our hypothesis. Linkage between HDAC2 modulation and H4k16 acetylation has 
been shown in breast cancer [65].  
By identifying the detailed roles that HDACs play in DNA damage responses by remodelling 
chromatin, we hope to better understand the molecular processes that underpin nuclear structure 
and identify novel mechanisms that control responses to chemotherapy.  
 
Materials and Methods 
Cell culture 
Cisplatin-sensitive PE01 and cisplatin-resistant PE04 ovarian cancer cell lines derived in our 
laboratory [30] were cultured as monolayers in RPMI 1640 supplemented with 10% heat-inactivated 
foetal calf serum (FCS) and penicillin/streptomycin (100 IU/mL) in 5% CO2 at 37°C.  
Ovarian cancer xenografts  
Two ovarian cancer patient-derived xenograft models were previously established in our 
laboratory: OV1002 and HOX424 [66]. Female adult CD-1 nude mice housed in individually ventilated 
cages were treated with carboplatin (50 mg/kg i.p.) on day 0, and tumor samples were collected on 
days 0, 1, 4, 7, and 14 after treatment. Tumors were formalin fixed and paraffin embedded (FFPE). 
The OV1002 xenograft model was markedly more sensitive to carboplatin treatment than the 
HOX424 model [31]. Xenograft studies were undertaken under a UK Home Office Project Licence in 
accordance with the Animals (Scientific Procedures) Act 1986, and the University of Edinburgh 
Animal Ethics Committee approved the study protocol. 
Nuclear texture analysis 
Confocal microscopy images were obtained using a Nikon A1R Confocal Microscope (Nikon 
Corporation, Tokyo, Japan) and images were viewed in NIS Viewer (Nikon). Cells were grown on 
chamber slides for the periods specified and fixed in 10% formalin in PBS for 10 min. After washing 
three times with PBS-0.05% Tween 20, slides were counterstained with anti-fade reagent with DAPI 
(Invitrogen, P36931; Thermo Fisher Scientific, Waltham, MA). Nuclear texture was analysed using 
Image J software. Briefly, after input of 8-bit images, fully focused areas containing tumor cells were 
marked as regions of interest (ROI) and individual nuclei selected. Nucleus counter and GLCM (grey-
level co-occurrence matrix) [67] manager plugins were performed on each image and five 
parameters associated with texture obtained: correlation, contrast, angular second moment (ASM), 
inverse different moment (IDM), and entropy. GLCM [67, 68] is a second-order texture calculation 
that considers the distance and angle relationship between two-pixel groups in the original greyscale 
image under the same intensity of grey pixels within a defined area. Texture features were regarded 
as positively or negatively associated with chromatin patterns (homogeneity, heterogeneity, and 
contrast) as previously described [28, 29]. 
siRNA knockdown of HDAC2 
Loss of HDAC2 function was achieved with siRNA transfection of cells in 60mm cell culture 
dishes according to the manufacturer’s instructions. Briefly, siRNA duplex-LipofectamineTM RNAiMAX 
complexes (Life Technologies, Thermo Fisher Scientific) were prepared as follows. 10-100 pmol 
siRNA duplex was diluted in 500μl Opti-MEM® I Medium (Life Technologies) without serum in each 
cell culture dish and mixed gently. The duplex sequences were: GACAAACCAGAACACUCCAGAAUAU 
and AUAUUCUGGAGUGUUCUGGUUUGUC. A negative scrambled stealth siRNA duplex with similar 
GC content (low GC duplex) to the target was used as control. 0.8 μl LipofectamineTM RNAiMAX  was 
added to each dish containing diluted siRNAs and incubated at room temperature for 20 min. After 
incubation, cells were diluted in complete growth medium without antibiotics at 700,000 – 800,000 
cells/5mL to ensure a cell density of 30-50% 24h after seeding, and 5 mL was added to each well. 
Controls were untransfected (no transfection agents), mock (only LipofectamineTM RNAiMAX 
mixture), and negative control (random RNAi duplex). The cells and the complexes were incubated 
for 24-120 h at 37°C in full serum without antibiotics. For drug treatment, cisplatin was added after 
48 h of transfection and cells were collected after several time points as indicated. 
Protein extraction from mammalian cell lines 
Cultured cells were washed in cold PBS and lysed by scraping in ice-cold isotonic lysis buffer 
(50mM Tris-HCl (pH7.5), 5mM EGTA (pH 8.5), 150mM NaCl, 1% Triton X-100) supplemented with 
aprotinin (10 μg/mL) and a ‘Complete’ Protease Inhibitor Cocktail Tablet (Roche, 11836153001) for 
30 min on ice. Lysates were centrifuged for 6 min at 13,000 × g and the supernatant stored at -70°C. 
Protein concentrations were determined using the bicinchoninic acid (BCA) assay (Sigma, BCA-1; 
Sigma-Aldrich, St. Louis, MO). 
Western blotting 
After SDS-PAGE using 10% polyacrylamide gels, resolved proteins were transferred to 
nitrocellulose membranes at 30V, 4°C overnight. After transfer, membranes were rinsed in PBST and 
blocked with Li-Cor Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE; diluted 50:50 in PBS) 
for 1h at room temperature before probing overnight at 4°C with the appropriate primary antibody 
in Li-Cor Odyssey Blocking Buffer. Primary antibodies were rabbit and obtained from Cell Signaling 
Technology (Beverly, MA) and used at 1:1000 unless otherwise indicated: anti-HP1 alpha (#2623), 
anti-HP1 beta (Abcam/ab10478), anti-HP1 gamma (#2619), anti-HDAC1 (mouse, #5356), anti-HDAC2 
(#2540), anti-HDAC3 (Abcam (Cambridge, UK) ab32369), anti-HDAC4  (Abcam ab32534),  anti-HDAC8 
(Abcam ab39664), anti-AMT (1:750 Abcam ab67998, mouse),  anti-pATM (Ser1981; #4526), anti-ATR 
(Abcam ab2905), anti-pATR (Ser428; #2853), anti-pBRCA1(Ser1524; #9009), anti-γH2AX (#2577), 
anti-Rad51 (H-92) (Santa Cruz Biotechnology, Dallas, TX; sc-8349), anti-α-tubulin (1:6000 Mouse 
Abcam ab7291), anti-β-tubulin (1:6000 Abcam ab6046), anti-GAPDH (1:8000 Mouse Abcam ab8245). 
Membranes were washed with PBS-Tween20 before incubation with fluorescently-labelled 
secondary antibodies diluted in Odyssey Blocking Buffer (50:50 in PBST) at 1:10,000 dilution. Mouse-
derived primary antibodies were detected using an anti-mouse fluorescently-labelled secondary 
antibody (680nm wavelength), whilst rabbit-derived primary antibodies were detected using an anti-
rabbit fluorescently-labelled secondary antibody (800nm wavelength) (45 min incubation). By 
combining a mouse primary with a rabbit primary along with their respective secondary antibodies, 
dual-labelled blots were obtained. Membranes were scanned on the Li-Cor Odyssey scanner, and the 
fluorescence value (integrated intensity, I.I.) corresponded to protein expression levels. Αlpha-
tubulin (Mouse Abcam ab7291) was used as loading control. 
RNA preparation and real time polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cultured cells using the Qiagen Mini RNeasy Kit according to the 
manufacturer’s instructions (Qiagen, Limburg, NL). The concentration and quality of RNA were 
assessed by NanoDrop. 1μg of total RNA from each individual sample was reverse transcribed using 
the QuantiTect Reverse Transcription kit (Qiagen) following the manufacturer’s instructions to 
produce 20μL of cDNA, which was quantified using Rotorgene (Corbett Research, San Francisco, CA) 
and the QuantiTect SYBR Green system (Qiagen) following the manufacturers’ instructions. For PCR, 
a 13-fold dilution of the cDNA mixture (10-fold dilution for standard curve) and a 10-fold dilution of 
primers for HDAC8 and β-actin (Qiagen) were used. A 15ul mixture of 7.5μl 2xQuantiTect SYBR 
Green iMaster Mix, 1.5 μL primer mix (0.3 μM), 2.5mM of MgCl2, and 1.5 μL cDNA was prepared in 
RNase-free water for the PCR reactions. PCR was performed as follows: 95°C for 15min; 45 cycles at 
94°C for 15s, 56°C for 30s, 72°C for 30s; 72°C for 5min followed by melting from 55°C to 95°C at 
0.2°C/s. 
Immunofluorescence (IF) on xenografts 
4μm TMA sections were deparaffinised in xylene for 5 min and rehydrated through graded 
ethanol. For antigen retrieval, sections were treated with 0.15mM sodium citrate, pH 6.0 or Tris-
EDTA, pH9.0 using a microwave pressure cooker for 5 min. Sections were rinsed in 0.05% PBST, 
blocked in 3% hydrogen peroxide and serum-free protein block (Dako, Glostrup, Denmark; #X0909), 
10 min each. After blocking, slides were incubated with primary antibodies diluted in second primary 
antibody (mouse anti-cytokeratin, Invitrogen, #18-0132) in Dako antibody diluents (1:25) for 1h at 
room temperature or overnight at 4°C. Primary antibodies were rabbit from Cell Signaling unless 
otherwise indicated: anti-HP1 alpha (#2623; 1:100 dilution), anti-HP1 beta (Abcam ab10478; 1:150), 
anti-HP1 gamma (#2619; 1:400 dilution), anti-HDAC1 (mouse #5356; 1:25 dilution), anti-HDAC2 
(#2540; 1/100 dilution), anti-HDAC3 (Abcam ab32369; 1/100 dilution), anti-HDAC4  
(Abcam/ab32534; 1/100 dilution)  and anti-HDAC8 (Abcam/ab39664; 1/100 dilution). Sections were 
rinsed in 0.05% PBST three times followed by incubation with secondary antibodies for 1 h at room 
temperature with a 1:25 dilution of goat-anti-mouse Alexa 555 antibody (Invitrogen, #A21422). After 
rinsing, sections were incubated with target signal amplification diluents and Cy5 tyramide at 1:50 in 
the dark for 10 min at room temperature for target visualisation. Finally, slides were rinsed, 
dehydrated in 80% ethanol for 1 min, air dried in the dark, and counterstained and cover-slipped 
using Prolong Gold anti-fade reagent with DAPI (Invitrogen, P36931).  
IF was analysed using the Automated QUantitative Analysis (AQUA) system (HistoRx, New 
Haven, CT) as previously described [69]. For each immunofluorescence image, AQUAnalysis software 
evaluated the quantity (in AQUA units=Au) of target protein expression (through Cy-5-tyramide) 
within the cytoplasm (identified by cytokeratin) and nuclei (DAPI). Images were examined to exclude 
imaging faults and normal tissue, thus target protein expression was scored only in invasive cancers. 
Cores containing <5% epithelium were automatically excluded to ensure tissues were representative 
of tumors [70]. The final normalised AQUA score detecting the fluorescence correlates with the 
expression level of target protein. 
 
Sulforhodamine B cell proliferation assay 
Cells were harvested in log phase, counted using a haemocytometer, and optimal initial 
numbers of cells in 200 uL per well were seeded into 96 well cell culture plates for 72h. After 0 to 6 
days incubation with small molecules, cells were fixed in 25% cold trichloroacetic acid (50uL/well), 
and incubated for 1 h at 4°C. Plates were washed, air-dried, and stained with sulforhodamine B dye 
(0.4% solution in 1% acetic acid, 50 μl/well) for 30 min. After washing with 1% acetic acid, plates 
were dried. 100uL Tris buffer (10mM, pH 10.5) was added into each well 1 h prior to reading and the 
optical density (OD) was recorded using a Biohit BP800 Microplate reader (Biohit, Helsinki, Finland) 
at 540 nm. 
Cell cycle analysis 
Cells were harvested and plated as described for western blotting. At the time points 
indicated, cells were trypsinised and transferred to 5 mL BD Falcon tubes (BD Biosciences). Citrate 
buffer (trisodium citrate (301287F, BDH Laboratory Supplies, Poole, UK), 121mg Tris Base (T1378, 
Sigma), 1044 mg spermine tetrahydrochloride (S2876, Sigma) and 2mL Nonidet NP40 (N3516, Sigma) 
in 2000mL distilled water, pH7.6) was added after centrifugation. The following solutions were 
added in sequence prior to analysis: 450uL solution A (0.003% trypsin type IX-S (T0303, Sigma) in 
citrate buffer, pH7.6) for 2 min, solution B (0.05% trypsin inhibitor (T9253, Sigma) and 0.01% RNAse 
A (R4875, Sigma) in citrate buffer pH7.6) for 10 min, and solution C (0.0416% propidium iodide 
(81845, Sigma) and 0.1% spermine tetrahydrochloride (S2876, Sigma) in 500 mL citrate buffer pH7.6) 
for 10 min in the dark. Apoptosis was detected at 24 h using the TACS Annexin V-FITC Kits (R &D 
Systems) according to the manufacturer’s protocol. Flow cytometry was performed using a BD 
FACSAriaII SORP (Becton Dickinson, Franklin Lakes, NJ). BD FACSDiva software (Becton Dickinson, 
Version 6.1.2) was used for instrument control and Flowjo software (Version 7.6.5) for Data analysis. 
Quantitative analysis of γH2AX foci formation in cells 
Cells were grown and stained as described above using anti-phospho-histone H2AX (ser139, 
γH2AX; Millipore 05-636) primary antibody. After mounting with DAPI and air-drying, cells were 
visualised with a BriteMAC or MacRd microscope. Nuclear images were taken with IPLab software 
with single filters for each channel and the same exposure for each set of experiments. For each 
slide, over 100 nuclei were counted for foci formation. The number of γH2AX foci in each nucleus 
was counted by the PZ Foci EZ plugin in ImageJ as described (available at www.pzfociez.com). Briefly, 
a nuclear mask defining ROIs was first created for each channel, and then the foci number was 
automatically counted in the channel within the defined ROI.  
Statistical analysis 
 
Student’s t-test was used to compare two independent samples. One-way ANOVA followed 
by the Tukey test was for multiple comparisons of groups with equal variance. Pearson correlations 
were performed for IF correlations. The Wilcoxon signed-rank test was used to compare target 
protein expression differences between the pre- and post-treatment samples from patients, and the 
Mann-Whitney test was performed to compare xenograft data. All data were analysed using 
GraphPad Prism (GraphPad Software Inc., La Jolla, CA), and a p-value <0.05 was considered 
statistically significant. 
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Figure legends 
 
Figure 1.   Nuclear morphology changes in different clinical and experimental settings. Similar 
nuclear texture changes occur in: A. ovarian tumors after chemotherapy; B. breast 
tumors after neoadjuvant therapy; C. colorectal tumors after radiotherapy; D. 
ovarian tumor xenografts after carboplatin treatment; and E. the ovarian cancer cell 
line PEO1 after cisplatin treatment. A-D are formalin-fixed, paraffin embedded 
sections cut from tumor samples and stained with H&E. E shows PEO1 cell cytospins 
using the Feulgen nuclear stain. 
Figure 2. Alterations in nuclear texture in vitro and in vivo after treatment with platinum 
drugs or radiotherapy. A. Changes in nuclear texture in PEO1 cells after irradiation or 
cisplatin treatment. PEO1 cells were grown on coverslips and treated with ionising 
radiation (6Gy) or cisplatin (6uM) for 24h, and nuclei were stained with DAPI for 
visualisation using a fluorescence microscope. At least 100 nuclei were included in 
each experiment. Nuclear texture was analysed by measuring five texture 
parameters (angular second moment, correlation, entropy, inverse different 
moment, and contrast) using Image J software. Data are presented as the average 
change (%) in the treated group for each parameter over the control group. B. 
Representative images from H&E-stained OV1002 ovarian tumor samples either 
untreated or after carboplatin (50 mg/kg) treatment in vivo. H&E stained images 
were acquired under 40x magnification. C. Nuclear texture parameter analysis in 
xenografts with and without carboplatin treatment on Day 2. Data for each spot 
represents the average value of each single sample with the number of nuclei 
analysed per sample ranging from 16 to 213 (average 103). Mann-Whitney U test (2-
tailed); *P<0.05, **P<0.01   D. Changes in chromatin patterns in PEO1 cells after 
cisplatin (6uM) or radiation (6Gy) treatment for 24h, and in OV1002 xenografts in 
vivo after carboplatin treatment, measured by parameters describing nuclear 
texture using Image J. The (+) and (-) represent positive and negative correlations 
with each type of chromatin pattern, respectively, and the arrows indicate the 
direction of change for each pattern. 
 
 
Figure 3. Expression of HDAC2 and heterochromatin proteins after cisplatin incubation.           
A. Western blots for HDAC2, HP1α, HP1β, and HP1γ in PEO1 and PEO4 cells with or 
without cisplatin treatment (6 uM, 24h). Membranes were probed with the 
indicated antibodies, and tubulin was used as a loading control. B. HDAC2 and HP1 
protein expression detected by immunofluorescence. Cells were seeded on cover 
slips and fixed as described in the Materials and Methods in PEO1 cells after cisplatin 
treatment for 6h and 24h. Alexa488 (green channel) and DAPI (blue channel) were 
used to stain target proteins and the nuclei, respectively. Images were taken using a 
confocal microscope. C. Expression of HDAC2, HP1α, HP1β, and HP1γ mRNA in PEO1 
cells measured by RT-PCR as described in the Materials and Methods. Relative 
expression of the target gene was calculated as the average ΔCt and normalized to 
that of the housekeeping gene β-actin. Results are as presented as mean ±SD from 
biological triplicates. *p<0.05, **p<0.01 (Student’s t-test). 
Figure 4. Expression of HDAC2, HP1α, HP1β and HP1γ in the OV1002 and HOX424 ovarian 
xenograft tumor models on Day 7 after carboplatin treatment. The sample TMA was 
probed with the indicated antibodies and expression levels were quantified by 
AQUA analysis. Boxplots depict AQUA scores representing the expression of 
proteins. Data was compared between control group (red bar) and carboplatin-
treated group (blue bar) within the platinum sensitive model (OV1002) and resistant 
model (HOX424), respectively. Man-Whitney analysis was performed and P values 
are indicated. 
Figure 5. Time-dependent expression of DNA damage response proteins in PEO1 cells. Cells 
were seeded and treated with or without cisplatin (6μM), and protein lysates were 
collected every 24h after treatment from 0h to 96h. Western blotting was 
performed to detect expression of pBRCA1, γH2AX, pATM, ATM, pATR, and ATR. 
Membranes were probed with the indicated antibodies, and tubulin was used as a 
loading control. Experiments were performed at least three times acquiring similar 
results. Blots from one representative experiment are shown. 
Figure 6.  The effect of siHDAC2 knockdown on expression of other HDAC family members, 
HP1s, and DNA damage response proteins by western blotting in PEO1 cells alone 
(A) and in the presence / absence of cisplatin (B). Protein was lysed after HDAC2 was 
knocked down after 72 h using reverse transfection. Non-transfection (control), 
mock, and siRNA negative control were used as controls. Membranes were probed 
with the indicated antibodies, and tubulin was used as a loading control. 
Experiments were performed at least three times acquiring similar results. Blots 
from one representative experiment are shown. In (B), cells were treated with 
cisplatin (6μM) after 72h incubation with mock (lane 1), siRNA negative control (lane 
2), or HDAC2 siRNA duplexes (10pmol in 6mL, lane 3). Protein lysates were collected 
at 6h, 24h, 48h, and 72h after cisplatin treatment and analysed by western blotting 
of DNA damage response proteins; tubulin was used as loading control. Experiments 
were performed at least three time acquiring similar results. Blots from one 
representative experiment are shown. 
Figure 7. Immunofluorescence for γH2AX foci in PEO1 cells. Cells were grown and treated as 
described before, and images were taken after 24 h treatment of cisplatin in cells 
with or without HDAC2 siRNA. Antibodies against H2AX phosphorylation at Ser 139 
were used to probe cellular γH2AX foci (red channel), and DAPI was applied for 
nuclear staining (blue channel). A. Representative images from one experiment are 
shown. >100 cells in each group were included for one experiment, and three 
independent experiments were performed.  B. Distribution of γH2AX foci / cell in 
PEO1 cells. 
 
Figure 8. The effect of HDAC2 knockdown on cell number (A), cell cycle distribution (B), and 
apoptosis (C) in PEO1 cells. A SRB assay profile for growth inhibition of cisplatin on 
PEO1 cells with (green line) and without (blue line) HDAC2 knockdown. Cells were 
reverse transfected with HDAC2 siRNA, followed by treatment with cisplatin for 72h. 
Three controls were included as described before. B. Percentages of the populations 
selected in G0/1, S, G2/M phases of the cell cycle were detected by flow cytometry. 
Columns represent the mean percentage of triplicate independent samples. Error 
bars represent SD. The Brown-Forsythe test followed by Games-Howell post-hoc test 
were performed to compare groups for each phase. C. The effect of HDAC2 
knockdown on apoptosis in PEO1 cells using the annexin V assay is shown. Cell 
number percentages of the population selected with positive annexin V staining 
were detected by flow cytometry after cisplatin treatment for 72h, and data are 
separated into early and late apoptosis based on propidium Iodide (PI) signal. 
Columns represent the mean percentage of triplicate independent samples. Error 
bars represent SD. One-way ANOVA analysis was performed to compare data among 
groups, and the Tukey HSD pot HOC test was used to compare groups. 
Figure 9. Changes in nuclear texture features in PEO1 cells treated with TSA (A) or transfected 
with HDAC2 siRNA before cisplatin treatment (B).  A. PEO1 cells were grown on 
coverslips and treated with TSA (250nM) for 24h, and nuclei were stained with DAPI 
for visualisation using a fluorescence microscope. At least 100 nuclei were included 
in one experiment. Nuclear texture was analysed by measuring five texture 
parameters (angular second moment, correlation, entropy, inverse different 
moment, and contrast) in Image J software. Data are presented as the average 
change (%) in TSA treated group for each parameter over control group. B. PEO1 
cells were grown on coverslips, transfected with HDAC2 siRNA for 72h, and treated 
with cisplatin (6μM) for a further 24h. Nuclei were stained with DAPI for 
visualisation using fluorescence microscopy. At least 100 nuclei were included in 
each group in one experiment. Nuclear texture was analysed by measuring five 
texture parameters (angular second moment, correlation, entropy, inverse different 
moment, and contrast) using Image J. 
 
Supporting Information 
Supplementary Figure 1  Assessment of HDAC2 protein expression by immunofluorescence 
(A) or western blotting (B) after HDAC2-targeted siRNA transfection 
in PEO1 cells. A. Representative images for HDAC2 expression 
detected by immunofluorescence. PEO1 cells were seeded on cover 
glasses and fixed as described in Materials and Methods after siRNA 
transfection (10pmol or 100pmol in 6mL) for 72h, and 
untransfected, mock, and negative treatment were used as control 
groups. Alexa488 (green channel) and DAPI (blue channel) were 
used to stain target proteins and nuclei, respectively. Pictures were 
taken using a confocal microscope. B. Assessment of HDAC2 protein 
expression by western blotting after HDAC2-targeted siRNA 
transfection in PEO1 cells. Cells were reverse transfected (as 
described in the methods) with siRNA (10pmol or 100pmol in 6mL) 
targeting HDAC2, and untransfected group (Ctr), mock group, and 
negative control were included as controls. Total protein was 
extracted from the cells at 48h, 72h, 96h, and 120h after 
transfection. Western blotting was performed to detect expression 
of HDAC2. Membranes were probed with the indicated antibodies, 
and tubulin was used as loading control.  
Supplementary Figure 2.  The effect of siHDAC2 knockdown on expression of other HDAC 
family members, HP1s and DNA damage response proteins by 
western blotting in PEO4 cells in the presence / absence of cisplatin. 
Protein was lysed after HDAC2 was knocked down after 72h using 
reverse transfection. Non-transfection (control), mock, and siRNA 
negative control were used as controls. Membranes were probed 
with the indicated antibodies, and tubulin was used as a loading 
control. Experiments were performed at least three times, acquiring 
similar results. Blots from one representative experiment are 
shown. In (B), cells were treated with cisplatin (6μM) after 72h 
incubation with mock (lane 1), siRNA negative control (lane 2), or 
HDAC2 siRNA duplexes (10pmol in 6mL, lane 3). Protein lysates were 
collected at 6h, 24h, 48h, and 72h after cisplatin treatment and 
analysed by western blotting of DNA damage response proteins; 
tubulin was used as loading control. Experiments were performed at 
least three time acquiring similar results. Blots from one 
representative experiment are shown. 
Supplementary Figure 3.   Immunofluorescence for γH2AX foci in PEO4 cells. Cells were grown 
and treated as described before, and images were taken after 24h 
treatment of cisplatin in cells with or without HDAC2 siRNA. 
Antibodies against H2AX phosphorylation at Ser 139 were used to 
probe cellular γH2AX foci (red channel), and DAPI was applied for 
nuclear staining (blue channel). A. Representative images from one 
experiment are shown. > 100 cells in each group were included for 
one experiment, and three independent experiments were 
performed. B. Distribution of γH2AX foci / cell in PEO4 cells 
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